- Home
- STTK vs CPHC Comparison
STTK vs CPHC Comparison
Compare STTK & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CPHC
- Stock Information
- Founded
- STTK 2016
- CPHC 1994
- Country
- STTK United States
- CPHC United States
- Employees
- STTK N/A
- CPHC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CPHC Services-Misc. Amusement & Recreation
- Sector
- STTK Health Care
- CPHC Consumer Discretionary
- Exchange
- STTK Nasdaq
- CPHC Nasdaq
- Market Cap
- STTK 83.8M
- CPHC 92.5M
- IPO Year
- STTK 2020
- CPHC 1994
- Fundamental
- Price
- STTK $1.92
- CPHC $16.43
- Analyst Decision
- STTK Hold
- CPHC
- Analyst Count
- STTK 6
- CPHC 0
- Target Price
- STTK $2.67
- CPHC N/A
- AVG Volume (30 Days)
- STTK 1.6M
- CPHC 2.2K
- Earning Date
- STTK 08-14-2025
- CPHC 11-06-2025
- Dividend Yield
- STTK N/A
- CPHC 1.68%
- EPS Growth
- STTK N/A
- CPHC N/A
- EPS
- STTK N/A
- CPHC 0.03
- Revenue
- STTK $2,997,000.00
- CPHC $60,069,270.00
- Revenue This Year
- STTK N/A
- CPHC N/A
- Revenue Next Year
- STTK N/A
- CPHC N/A
- P/E Ratio
- STTK N/A
- CPHC $566.37
- Revenue Growth
- STTK N/A
- CPHC N/A
- 52 Week Low
- STTK $0.69
- CPHC $16.15
- 52 Week High
- STTK $3.95
- CPHC $22.93
- Technical
- Relative Strength Index (RSI)
- STTK 72.13
- CPHC 38.78
- Support Level
- STTK $1.68
- CPHC $16.40
- Resistance Level
- STTK $2.04
- CPHC $16.87
- Average True Range (ATR)
- STTK 0.19
- CPHC 0.27
- MACD
- STTK 0.09
- CPHC 0.05
- Stochastic Oscillator
- STTK 89.29
- CPHC 2.88
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.